🔗 Share this article

As America undertakes sweeping adjustments to its vaccination recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning Covid shots in the pandemic and has zeroed in on possible deaths following Covid vaccination in her brief position at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Program

Health officials planned to announce sweeping revisions to the pediatric vaccination calendar in December, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with many the global community with little proof for public health gain. The announcement has been pushed back until the next year.

In place of the top vaccines chief, Dr. Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A Shift at the FDA

The acting appointment may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain pediatric immunization guidelines in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.

Concerns Over Background

Dr. Høeg has no apparent background in pharmaceutical research, regulation or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for running the CDER, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “understand legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who led CBER have had.”

This division has an immense workload at the agency, she stated.

“Everybody just focuses on the new drug program, but the generic drug division approves numerous generic medications. There’s a biosimilars division, non-prescription drug unit and more, and all of those have to be managed,” she said. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a significant management component to the role, which oversees more than 5,000 employees. “It is a enormous management job, if you execute it properly,” Woodcock added.

Agency Reaction and Contentious Policies

In response to concerns about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on immunizations, a spokesperson said that the “concerns stem from incorrect assumptions”.

“Her experience is consistent with the duties of her position,” the spokesperson explained, citing the period Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial expedited review system, a controversial one-day drug-approval program that apparently troubled her predecessors. “By what process are these medications being selected for this fast-track system? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of all drugs, aside from immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, history, some experts observe. She published a study using non-validated crowd-sourced reports to assess the incidence of heart inflammation after Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming federal leadership included revising rules for new vaccines and discontinuing “optional” immunizations, she said after the election on a audio program. At the agency, Dr. Høeg has allegedly proposed preventing adolescent males from getting COVID-19 vaccinations.

“She is an thorough true believer who commences with her preconceived notions and tailors the evidence to retrofit the data in a highly misleading, dishonest fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other contrarians, {like|